

Form 51-102F3

MATERIAL CHANGE REPORT UNDER 7.1(1) OF NATIONAL INSTRUMENT 51-102

ITEM 1 NAME AND ADDRESS OF COMPANY

Biosenta Inc.
1120 Finch Avenue West, Suite 503
Toronto, Ontario M5J 3H7

ITEM 2 DATE OF MATERIAL CHANGE

March 27, 2013

ITEM 3 NEWS RELEASE

A news release announcing the material change was issued by the Company on March 26, 2013 through CNW.

ITEM 4 SUMMARY OF MATERIAL CHANGE

See the press release issued March 26, 2013 attached as Schedule "A" hereto.

ITEM 5 FULL DESCRIPTION OF MATERIAL CHANGE

See the press release issued March 26, 2013 attached as Schedule "A" hereto.

ITEM 6 RELIANCE ON SUBSECTION 7.1 (2) OF NATIONAL INSTRUMENT 51-102

This report is not being filed on a confidential basis.

ITEM 7 OMITTED INFORMATION

Not applicable.

ITEM 8 EXECUTIVE OFFICER

The following officer is knowledgeable about the material change and this report:

Bruce Lewis
President and Chief Executive Officer
416 410 2019

ITEM 9 DATE OF REPORT

DATED in the Province of Ontario, this 27th day of March, 2013.

Schedule "A"

Biosenta, Inc. continues expansion strategy, cancels exclusivity agreement with FT Royal

TORONTO, March 26, 2013 Biosenta, Inc. (CNSX: ZRO) (the "Company") is pleased to announce the mutual termination of its exclusive distribution agreement with FT Royal Products Group effective immediately. As previously announced by Biosenta, the Company has hired Mr. Scott Butterworth as Vice-President of Marketing and Sales in a strategic move to internalize the marketing and sales functions that will enable the Company to effectively manage the expansion of its Zeromold products within the North American market.

About BIOSENTA Inc.

BIOSENTA Inc.'s line of retail anti-microbial products will effectively kill mould, bacteria and fungi on contact and prevent re-growth. These products address the demand created by the mounting health and environmental concerns. Mould can affect the immune system, nervous system, liver, kidneys, blood and cause brain damage.

BIOSENTA will also manufacture and distribute an anti-microbial filler. Calcium Carbonate is one of the most common fillers used industrially. It is susceptible like other fillers that hold moisture to attracting mould. Annual global revenue in the calcium carbonate filler industry approximates 140 billion dollars. BIOSENTA will produce anti-microbial filler that performs 'filling' and 'bulking' functions like calcium carbonate. BIOSENTA's filler product will not attract moisture and consequently mould infestation. BIOSENTA's filler with its anti-microbial high pH core in individual particles will enhance commercial product life and eradicate a broad spectrum of known bacteria, fungi, algae and other micro-organisms by suppression of their reproduction.

Forward-Looking Information

This release may contain forward-looking statements information and statements which constitute "forward-looking information" under Canadian securities law and which may be material regarding, among other things, the Company's beliefs, plans, objectives, estimates, intentions and expectations with respect to its capital and funding plans. Inherent in the forward-looking information and statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to control or predict, which give rise to the possibility that the Company's predictions, forecasts, expectations or conclusions will not prove to be accurate, that its assumptions may not be correct and that the Company's plans, objectives and statements will not be achieved. Actual results or developments may differ materially from those contemplated by the forward-looking information and statements. Consequently, undue reliance should not be placed on such forward-looking statements.

On behalf of the Board of Directors of BIOSENTA Inc.

Bruce Lewis
Chairman

The CNSX has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release. Neither the CNSX nor its Regulation Services Provider (as such term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Bruce Lewis, President & Chief Executive Officer
BIOSENTA Inc.
1120 Finch Avenue West, Suite 503,
Toronto, Ontario M3J 3H7
(416) 410 2019

Investor Relations contact:
Investor Cubed Inc.
Neil Simon
647-258-3311
888-258-3323
info@investor3.ca

